Ide-cel Without Front-Line ASCT: KARMMA-2 Cohort 2B | Xavier Leleu, MD, MSc, PhD, EHA 2024

Xavier Leleu, MD, MSc, PhD, explains the results of the KARMMA-2 study, a study analyzing the use of Ide-cel in treating patients with high risk, early relapse multiple myeloma.
library.ehaweb.org/eha/2024/e...
The HealthTree Foundation for Multiple Myeloma brings information from the experts to the patients! Learn more at www.healthtree.org/myeloma/co...
Donate to the HealthTree Foundation for Multiple Myeloma or learn more about additional myeloma support we offer here: give.healthtree.org/campaign/...
HealthTree Cure Hub helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at www.healthtree.org/
Follow HealthTree:
healthtreeformm
healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma